Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Biogen, Inc. ("Biogen" or the "Company") ( NASDAQ: BIIB ) in the United States District Court for the District of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Biogen securities between June 7, 2021 and January 11, 2022, both dates included, (the "Class Period"). Investors have until April 8, 2022 to apply to the Court to be appointed as lead plaintiff in the lawsuit.